# Data I/O Corp: financial statements, quarterly

DAIO · Nasdaq · CIK 351998 · [Technology](/sectors/technology.md) · fiscal year ends Dec 11

Pages: [Overview](/companies/daio.md) · [Financials](/companies/daio/financials.md) · [Filings](/companies/daio/filings.md) · [Insiders](/companies/daio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/daio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6,561](/filings/0001654954-24-014124.md) | [6,874 d](/filings/0001654954-25-003717.md) | [6,099](/filings/0001654954-25-005511.md) | [5,062](/filings/0001654954-25-009427.md) | [5,423](/filings/0001654954-25-012945.md) | [5,185 d](/filings/0001654954-26-003625.md) | [6,176](/filings/0001654954-26-005009.md) | [5,948](/filings/0001654954-26-007670.md) | [5,393](/filings/0001654954-25-012945.md) | [3,984 d](/filings/0001654954-26-003625.md) | [3,250](/filings/0001654954-26-005009.md) | [5,149](/filings/0001654954-26-007670.md) |
| Cost of revenue | $k | [3,041](/filings/0001654954-24-014124.md) | [2,883 d](/filings/0001654954-25-003717.md) | [2,879](/filings/0001654954-25-005511.md) | [2,305](/filings/0001654954-25-009427.md) | [2,499](/filings/0001654954-25-012945.md) | [2,479 d](/filings/0001654954-26-003625.md) | [2,988](/filings/0001654954-26-005009.md) | [2,988](/filings/0001654954-26-007670.md) | [2,659](/filings/0001654954-25-012945.md) | [2,270 d](/filings/0001654954-26-003625.md) | [1,641](/filings/0001654954-26-005009.md) | [2,214](/filings/0001654954-26-007670.md) |
| Gross profit | $k | [3,520](/filings/0001654954-24-014124.md) | [3,991 d](/filings/0001654954-25-003717.md) | [3,220](/filings/0001654954-25-005511.md) | [2,757](/filings/0001654954-25-009427.md) | [2,924](/filings/0001654954-25-012945.md) | [2,706 d](/filings/0001654954-26-003625.md) | [3,188](/filings/0001654954-26-005009.md) | [2,960](/filings/0001654954-26-007670.md) | [2,734](/filings/0001654954-25-012945.md) | [1,714 d](/filings/0001654954-26-003625.md) | [1,609](/filings/0001654954-26-005009.md) | [2,935](/filings/0001654954-26-007670.md) |
| Research and development | $k | [1,577](/filings/0001654954-24-014124.md) | [1,602 d](/filings/0001654954-25-003717.md) | [1,582](/filings/0001654954-25-005511.md) | [1,413](/filings/0001654954-25-009427.md) | [1,544](/filings/0001654954-25-012945.md) | [1,701 d](/filings/0001654954-26-003625.md) | [1,515](/filings/0001654954-26-005009.md) | [1,662](/filings/0001654954-26-007670.md) | [1,709](/filings/0001654954-25-012945.md) | [1,645 d](/filings/0001654954-26-003625.md) | [1,291](/filings/0001654954-26-005009.md) | [1,380](/filings/0001654954-26-007670.md) |
| Selling, general and administrative | $k | [2,006](/filings/0001654954-24-014124.md) | [2,211 d](/filings/0001654954-25-003717.md) | [2,498](/filings/0001654954-25-005511.md) | [1,910](/filings/0001654954-25-009427.md) | [1,705](/filings/0001654954-25-012945.md) | [2,292 d](/filings/0001654954-26-003625.md) | [2,050](/filings/0001654954-26-005009.md) | [2,142](/filings/0001654954-26-007670.md) | [2,418](/filings/0001654954-25-012945.md) | [2,572 d](/filings/0001654954-26-003625.md) | [3,462](/filings/0001654954-26-005009.md) | [2,279](/filings/0001654954-26-007670.md) |
| Operating income | $k | [(63.0)](/filings/0001654954-24-014124.md) | [178 d](/filings/0001654954-25-003717.md) | [(860)](/filings/0001654954-25-005511.md) | [(566)](/filings/0001654954-25-009427.md) | [(325)](/filings/0001654954-25-012945.md) | [(1,287) d](/filings/0001654954-26-003625.md) | [(377)](/filings/0001654954-26-005009.md) | [(844)](/filings/0001654954-26-007670.md) | [(1,393)](/filings/0001654954-25-012945.md) | [(2,503) d](/filings/0001654954-26-003625.md) | [(3,144)](/filings/0001654954-26-005009.md) | [(724)](/filings/0001654954-26-007670.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001654954-26-007670.md) | not reported | not reported | not reported | [873](/filings/0001654954-26-007670.md) |
| Income tax | $k | [16.0](/filings/0001654954-24-014124.md) | [34.0 d](/filings/0001654954-25-003717.md) | [41.0](/filings/0001654954-25-005511.md) | [353](/filings/0001654954-25-009427.md) | [0.0](/filings/0001654954-25-012945.md) | [(779) d](/filings/0001654954-26-003625.md) | [21.0](/filings/0001654954-26-005009.md) | [20.0](/filings/0001654954-26-007670.md) | [0.0](/filings/0001654954-25-012945.md) | [238 d](/filings/0001654954-26-003625.md) | [0.0](/filings/0001654954-26-005009.md) | [0.0](/filings/0001654954-26-007670.md) |
| Net income | $k | [(53.0)](/filings/0001654954-24-014124.md) | [144 d](/filings/0001654954-25-003717.md) | [(807)](/filings/0001654954-25-012945.md) | [(797)](/filings/0001654954-25-012945.md) | [(307)](/filings/0001654954-25-012945.md) | [(1,182) d](/filings/0001654954-26-003625.md) | [(382)](/filings/0001654954-26-007670.md) | [(742)](/filings/0001654954-26-007670.md) | [(1,362)](/filings/0001654954-25-012945.md) | [(2,750) d](/filings/0001654954-26-003625.md) | [(3,170)](/filings/0001654954-26-007670.md) | [(1,629)](/filings/0001654954-26-007670.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001654954-24-014124.md) | not reported | [(0.09)](/filings/0001654954-25-005511.md) | [(0.09)](/filings/0001654954-25-009427.md) | [(0.03)](/filings/0001654954-25-012945.md) | not reported | [(0.04)](/filings/0001654954-26-005009.md) | [(0.08)](/filings/0001654954-26-007670.md) | [(0.15)](/filings/0001654954-25-012945.md) | not reported | [(0.34)](/filings/0001654954-26-005009.md) | [(0.17)](/filings/0001654954-26-007670.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001654954-24-014124.md) | not reported | [(0.09)](/filings/0001654954-25-005511.md) | [(0.09)](/filings/0001654954-25-009427.md) | [(0.03)](/filings/0001654954-25-012945.md) | not reported | [(0.04)](/filings/0001654954-26-005009.md) | [(0.08)](/filings/0001654954-26-007670.md) | [(0.15)](/filings/0001654954-25-012945.md) | not reported | [(0.34)](/filings/0001654954-26-005009.md) | [(0.17)](/filings/0001654954-26-007670.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.9](/filings/0001654954-23-014113.md) | [6.6](/filings/0001654954-25-003717.md) | not reported | not reported | not reported | [4.3](/filings/0001654954-26-003625.md) | not reported | not reported | not reported | [5.2](/filings/0001654954-26-003625.md) | not reported | not reported |
| Current assets | $m | [23.8](/filings/0001654954-23-014113.md) | [24.6](/filings/0001654954-25-003717.md) | [23.9](/filings/0001654954-24-005992.md) | [22.1](/filings/0001654954-24-010421.md) | [22.2](/filings/0001654954-24-014124.md) | [21.2](/filings/0001654954-26-003625.md) | [21.0](/filings/0001654954-25-005511.md) | [20.6](/filings/0001654954-25-009427.md) | [19.5](/filings/0001654954-25-012945.md) | [17.3](/filings/0001654954-26-007670.md) | [15.0](/filings/0001654954-26-005009.md) | [22.2](/filings/0001654954-26-007670.md) |
| Total assets | $m | [26.3](/filings/0001654954-23-014113.md) | [27.4](/filings/0001654954-25-003717.md) | [26.2](/filings/0001654954-24-005992.md) | [24.1](/filings/0001654954-24-010421.md) | [24.8](/filings/0001654954-24-014124.md) | [25.0](/filings/0001654954-26-003625.md) | [24.5](/filings/0001654954-25-005511.md) | [24.1](/filings/0001654954-25-009427.md) | [22.7](/filings/0001654954-25-012945.md) | [20.2](/filings/0001654954-26-007670.md) | [17.6](/filings/0001654954-26-005009.md) | [24.6](/filings/0001654954-26-007670.md) |
| Current liabilities | $m | [5.7](/filings/0001654954-23-014113.md) | [6.2](/filings/0001654954-25-003717.md) | [5.8](/filings/0001654954-24-005992.md) | [4.5](/filings/0001654954-24-010421.md) | [4.5](/filings/0001654954-24-014124.md) | [5.1](/filings/0001654954-26-003625.md) | [5.0](/filings/0001654954-25-005511.md) | [5.1](/filings/0001654954-25-009427.md) | [5.1](/filings/0001654954-25-012945.md) | [5.0](/filings/0001654954-26-007670.md) | [5.7](/filings/0001654954-26-005009.md) | [11.5](/filings/0001654954-26-007670.md) |
| Shareholders' equity | $m | [19.6](/filings/0001654954-24-014124.md) | [20.3](/filings/0001654954-26-003625.md) | [19.6](/filings/0001654954-25-012945.md) | [18.9](/filings/0001654954-25-012945.md) | [19.2](/filings/0001654954-25-012945.md) | [17.6](/filings/0001654954-26-007670.md) | [17.5](/filings/0001654954-26-007670.md) | [17.2](/filings/0001654954-26-007670.md) | [16.0](/filings/0001654954-25-012945.md) | [13.5](/filings/0001654954-26-007670.md) | [10.5](/filings/0001654954-26-007670.md) | [11.9](/filings/0001654954-26-007670.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [241 d](/filings/0001654954-24-014124.md) | [967 d](/filings/0001654954-25-003717.md) | [(41.0)](/filings/0001654954-25-005511.md) | [(243) d](/filings/0001654954-25-009427.md) | [839 d](/filings/0001654954-25-012945.md) | [(1,550) d](/filings/0001654954-26-003625.md) | [109](/filings/0001654954-26-005009.md) | [(342) d](/filings/0001654954-26-007670.md) | [(343) d](/filings/0001654954-25-012945.md) | [(1,651) d](/filings/0001654954-26-003625.md) | [(2,227)](/filings/0001654954-26-005009.md) | [(2,939) d](/filings/0001654954-26-007670.md) |
| Capital expenditure | $k | [175 d](/filings/0001654954-24-014124.md) | [705 d](/filings/0001654954-25-003717.md) | [139](/filings/0001654954-25-005511.md) | [25.0 d](/filings/0001654954-25-009427.md) | [115 d](/filings/0001654954-25-012945.md) | [188 d](/filings/0001654954-26-003625.md) | [56.0](/filings/0001654954-26-005009.md) | [291 d](/filings/0001654954-26-007670.md) | [5.0 d](/filings/0001654954-25-012945.md) | [206 d](/filings/0001654954-26-003625.md) | [8.0](/filings/0001654954-26-005009.md) | [221 d](/filings/0001654954-26-007670.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [8,859](/filings/0001654954-23-014113.md) | [9,029](/filings/0001654954-24-005992.md) | [9,075](/filings/0001654954-24-010421.md) | [9,020](/filings/0001654954-24-014124.md) | [9,023](/filings/0001654954-25-005511.md) | [9.1](/filings/0001654954-25-009427.md) | [9.2](/filings/0001654954-25-012945.md) | [9,238](/filings/0001654954-26-005009.md) | [9,296](/filings/0001654954-26-007670.md) | [9.4](/filings/0001654954-25-012945.md) | [9,393](/filings/0001654954-26-005009.md) | [9,572](/filings/0001654954-26-007670.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,395,627 at 2026-07-31, from the cover of the [10-Q filed 2026-08-14](/filings/0001654954-26-007670.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.